Please login to the form below

Not currently logged in
Email:
Password:

Von Eschenbach in running for FDA job

Deadline for naming of permanent commissioner is approaching
 
Schering turns down Merck offer
NHS trusts to face tougher ratings tests
 
Pharma news in brief
NHS news in brief
R&D news in brief
Speculation is mounting that Andrew von Eschenbach, acting commissioner of the US Food and Drug Administration (FDA), is set to be nominated for the permanent job of running the regulatory agency.

Under US law, an acting commissioner can only serve up to 210 days before the president (George Bush) must designate a permanent commissioner. Von Eschenbach, 64, took the job temporarily in September after the resignation of Lester Crawford.

The FDA declined to comment on von Eschenbach' position. ìDr von Eschenbach defers to the White House to announce its intention regarding the nomination of FDA Commissioner,î it said in a statement. ìIn the meantime, he is pleased to serve as acting commissioner of the FDA at the request of the president and Secretary [Michael] Leavitt.î

Health and Human Services Secretary, Leavitt said last week that the White House would probably nominate a candidate ìin the very near futureî.

Some senators could oppose a von Eschenbach nomination; on his appointment as acting commissioner he was criticised for retaining his position as director of the National Cancer Institute, which some see as a conflict of interests. Von Eschenbach later gave up day to day running of the institute and has promised not to sit on or influence any discussions about cancer treatments.

US pharma industry association PhRMA refused to comment on its preferred candidate for the job although spokesman Jeff Trewhitt said von Eschenbach ìhas impressive research and management credentialsî.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
fox&cat

up to your ears in it? some pressure is helpful but too much of the wrong sort quickly takes its...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....